Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs Read More Feb 25, 2025
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases Read More Feb 6, 2025
Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus Read More Jan 23, 2025
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager Read More Jan 7, 2025
Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications Read More Dec 16, 2024
Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to Treat Myotonic Dystrophy Read More Dec 4, 2024
35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity Read More Nov 26, 2024
